Highlights

• Energy One soared after rejecting an unsolicited takeover proposal that valued the company at AU$17.00 per share.
• 4DMedical gained following strong quarterly growth, commercial expansion and strategic partnerships.
• Clarity Pharmaceuticals rallied as investors responded to commercialisation progress and clinical development milestones.

Three ASX-listed companies posted double-digit gains on Friday, attracting investor attention after releasing significant corporate updates. Stocks in Focus: 

• Energy One Limited (ASX: EOL) surged 31.80% to AU$14.30
• 4DMedical Limited (ASX: 4DX) climbed 13.08% to AU$3.63
• Clarity Pharmaceuticals Ltd (ASX: CU6) advanced 12.86% to AU$2.37

Energy One Rejects Revised Takeover ProposalEnergy One emerged as the session's standout performer after confirming it had received a revised unsolicited, non-binding proposal from Norway-based Volue AS to acquire the company for AU$17.00 per share, an increase from its earlier AU$16.50 proposal. However, the board unanimously rejected the offer, stating that it undervalued the company and presented execution risks. Directors also expressed confidence in Energy One's long-term growth strategy, citing continued earnings growth, margin expansion and its strong position in the global energy trading software market.

4DMedical Expands Commercial Footprint

Investor sentiment towards 4DMedical strengthened after the company reported a strong FY2026 quarter. Operating revenue increased 23% year-on-year to AU$7.2 million, while its SaaS platform expanded to 540 sites globally and delivered a record 105,970 scans during the quarter. The company also entered the U.S. outpatient market through a commercial agreement with SimonMed Imaging, launched new clinical programs, completed the acquisition of AI imaging company contextflow and finished the quarter with AU$278 million in cash, reinforcing confidence in its commercial growth strategy.

Clarity Advances Towards Commercialisation

Clarity Pharmaceuticals also attracted buying interest after highlighting continued progress across its radiopharmaceutical pipeline. During the quarter, the company strengthened its manufacturing network for 64Cu-SAR-bisPSMA, expanded preparations for commercial launch, advanced multiple Phase III clinical programs and maintained a strong cash position of AU$178.3 million. Management noted that recent manufacturing agreements, growing clinical evidence and ongoing regulatory progress continue to support its commercialisation strategy in the expanding oncology market.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au